Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimum

Patients with previously untreated advanced or metastatic renal cell carcinoma treated with Opdivo plus Yervoy experienced a 28% reduction in the risk of death vs. sunitinib at eight years from the...

Related Keywords

United States , Japan , South Korea , China , Taiwan , American , America , Dana Walker , Bristol Myers Squibb , Nizar Tannir , Instagram , Youtube , Facebook , Md Anderson Cancer Center , Ono Pharmaceutical Co , Drug Administration , Division Of Cancer Medicine , International Metastatic , Linkedin , Company Opdivo , American Society Of Clinical Oncology , Exchange Commission , Database Consortium , European Union , Department Of Genitourinary Medical Oncology , University Of Texas , Twitter , American Society , Clinical Oncology , Cancers Symposium , Hazard Ratio , Confidence Interval , Genitourinary Medical Oncology , Cancer Medicine , Bristol Myers , Myers Squibb , North America , Better Future , Fatal Immune Mediated Adverse , Full Prescribing Information , Allogeneic Hematopoietic Stem Cell , Multiple Myeloma , Thalidomide Analogue , Prescribing Information , Ono Pharmaceutical Collaboration , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Markets ,